Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy

Ghanem, Samar; Elsabaawy, Maha; Shebl, Nashwa; Abdelsameea, Eman; Othman, Warda; Elbassal, Fathia; Elgedawy, Gamalat; Elsabaawy, Dalia; Helal, Marwa

doi:10.1080/14787210.2020.1771180

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the groups differed significantly regarding albumin level (P value < 0.003). The present study observed a high statistically significant difference between HCC and HCV groups with regard to the type of drug regimen used; SOF+DAC+RBV was the most prevalent drug regimen in HCC group (P value < 0.001) and SOF+SIM was the safest drug regimen in the HCV group .These results are in agreement with a previous study of (Ghanem et al, 2020) who found that SOF+DAC+RBV was the most prevalent drug treatment for HCC. Similarly, another study (Abdelaziz et al, 2019) assured that SOF+DAC+RBV regimen was the most prevalent in HCC.…”

Section: Discussionsupporting

confidence: 91%

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus

Ghanm

Shebl

Sayed

et al. 2021

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Objective: This study aimed to assess the correlation between the genotyping of interleukin-10 (IL-10 polymorphism rs 1800871) and the incidence hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV) treated with direct acting antivirals (DAAs). Method: For 200 patients with HCV infection who completed DAA treatment and followed up for 1 year, IL-10 polymorphism SNP(-819) rs 1800871 analysis was conducted via real time polymerase chain reaction. During the follow-up period, 100 patients who developed HCC were selected and compared with 100 patients who did not develop any complications. Results: The studied patients were divided into two groups according to the incidence of complications after completion of DAA treatments. During the follow-up, 100 patients with HCV infection who developed HCC were selected and compared with 100 patients with HCV infection who did not develop any complications (positive control group). For the HCC group (n = 100), the mean age was 58.1 ± 6.4 years, with 92.7% being male and 7.3% being female; 91% had cirrhosis, 10% had lymphadenitis, 75% had splenomegaly, and 17% had ascites. In the positive control group (n = 100), mean age was 46.3 ± 9.4 years, with 68% being male and 32% being female; 20% had cirrhosis, 12% had splenomegaly, and 4.2% had ascites. The results demonstrated that sofosbuvir (SOF) + daclatasvir + ribavirin regimen was the most prevalent drug treatment for patients with HCC (72%), while SOF + Simeprevir was the most safe treatment for HCV infection among patients with HCC (2%). CT genotype was the most common genotype in the HCC group (56%), among different drug regimen (67.8%). T allele was the most prevalent in HCC group (61%), while the C allele was the least prevalent (39%). Conclusion: IL-10 genotyping may help in selecting the safest and most accurate drug regimen according to the safest genotype response relationship and follow-up of genotype resistance.

show abstract

Section: Discussionsupporting

confidence: 91%

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus

Ghanm

Shebl

Sayed

et al. 2021

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

show abstract

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C

Abdelaziz,

Abdelsameea,

Abdel-Samiee

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

The prevalence of HCV infection in Egypt has decreased following the introduction of direct-acting antiviral therapy. However, treatment response is influenced by various factors, particularly host immunogenetics such as IL-28B and FOXP3 polymorphisms. The current study examined the impact of SNPs in the FOXP3 gene promoter region on HCV-infected Egyptian patients, along with SNPs in the IL28B gene.This study involved 99 HCV patients who achieved SVR12 after a 12 week DAA treatment while 63 HCV patients experienced treatment failure. IL28B rs12979860 SNP was identified using real-time PCR, while IL28B rs8099917, FOXP3 rs3761548, and rs2232365 SNPs were analyzed using RFLP-PCR. Serum levels of IL28B and FOXP3 were quantified using ELISA technique in representative samples from both groups. The IL28B rs12979860 T > C (P = 0.013) and FOXP3 rs2232365 A > G polymorphisms (P = 0.008) were found to significantly increase the risk of non-response. Responders had higher IL28B serum levels (P = 0.046) and lower FOXP3 levels (P < 0.001) compared to non-responders. Regression analysis showed an association between IL28B rs12979860 and FOXP3 rs2232365 with treatment response, independent of age and gender. A predictive model was developed with 76.2% sensitivity and 91.9% specificity for estimating DAAs response in HCV patients.Our findings confirmed the IL28B rs12979860 T > C and FOXP3 rs2232365 A > G polymorphisms significantly affect DAA treatment response in HCV Egyptian patients. Lower levels of IL-28B along with higher levels of FOXP3 are linked to poor response. Our results may lead to new insights into DAA responsiveness contributing to personalized medicine and improving therapeutic decision-making for HCV patients. Graphical abstract

show abstract

WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations

et al. 2021

View full text Add to dashboard Cite

Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy

Cited by 3 publications

References 38 publications

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C

WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations

Contact Info

Product

Resources

About